1Division of Hematology-Oncology, Department of Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea
2Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Copyright © 2020 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Values are presented as number (%). HER2, human epidermal growth factor receptor 2; ECOG PS, Eastern Cooperative Oncology Group performance status; LN, lymph node; LMS, leptomeningeal seeding; ADC, adenocarcinoma; SQC, squamous cell carcinoma; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.
Characteristic | HER2 altered (n=36) | Exon20 insertion (n=22) | HER2 amplification (n=15) | p-value |
---|---|---|---|---|
Age at diagnosis (yr) | 58 | 60.2 | 56.4 | |
Sex | 0.093 | |||
Men | 20 (55.6) | 10 (45.5) | 11 (73.3) | |
Women | 16 (44.4) | 12 (54.5) | 4 (26.7) | |
ECOG PS | 0.819 | |||
0 | 4 (11.1) | 3 (13.6) | 1 (6.7) | |
1 | 30 (83.3) | 18 (81.8) | 13 (86.7) | |
2 | 2 (5.6) | 1 (4.5) | 1 (6.7) | |
Tobacco | 0.084 | |||
Never | 18 (50.0) | 14 (63.6) | 4 (26.7) | |
Former | 11 (30.6) | 5 (22.7) | 6 (40.0) | |
Current | 7 (19.4) | 3 (13.6) | 5 (33.3) | |
Stage at diagnosis | 0.753 | |||
I | 5 (13.9) | 2 (9.1) | 3 (20.0) | |
II | 3 (8.3) | 2 (9.1) | 1 (6.7) | |
III | 4 (11.1) | 2 (9.1) | 2 (13.3) | |
IV | 24 (66.7) | 16 (72.7) | 9 (60.0) | |
Metastasis sites | ||||
Bone | 21 (58.3) | 14 (63.6) | 8 (53.3) | 0.531 |
Pleura | 18 (50.0) | 12 (54.5) | 6 (40.0) | 0.385 |
Brain | 13 (36.1) | 8 (36.4) | 5 (33.3) | 0.850 |
Contralateral metastasis | 11 (30.6) | 6 (27.3) | 5 (33.3) | 0.728 |
Liver | 7 (19.4) | 7 (31.8) | 0 | 0.028 |
Distant LN | 7 (19.4) | 4 (18.2) | 3 (20.0) | 0.808 |
Adrenal | 4 (11.1) | 4 (18.2) | 0 | 0.131 |
LMS | 3 (8.3) | 2 (9.1) | 1 (6.7) | 1.000 |
Thyroid | 1 (2.8) | 1 (4.5) | 0 | 1.000 |
Histology | 0.021 | |||
ADC | 32 (88.9) | 22 (100) | 11 (73.3) | |
SQC | 4 (11.1) | 0 | 4 (26.7) | |
EGFR(+) | 0.002 | |||
Wild type | 30 (83.3) | 22 (100) | 9 (60.0) | |
Mutation | 6 (16.7) | 0 | 6 (40.0) | |
ALK(+) | 0.505 | |||
Wild type | 34 (94.4) | 20 (90.9) | 15 (100) | |
Mutation | 2 (5.6) | 2 (9.1) | 0 |
Patient No. | Amino acid change | Amino acid change | Total (n=22) |
---|---|---|---|
1 | E770_A771insAYVM | E770_A771insAYVM | 12 |
2 | E770_A771insAYVM | E770delinsEAYVM | 4 |
3 | E770_A771insAYVM | G776delinsVC | 3 |
4 | E770_A771insAYVM | V777delinsVGSP | 2 |
5 | E770_A771insAYVM | A771_Y772insYVMA | 1 |
6 | E770_A771insAYVM | - | - |
7 | G776delinsVC | - | - |
8 | E770_A771insAYVM | - | - |
9 | E770_A771insAYVM | - | - |
10 | A771_Y772insYVMA | - | - |
11 | G776delinsVC | - | - |
12 | E770_A771insAYVM | - | - |
13 | E770_A771insAYVM | - | - |
14 | E770_A771insAYVM | - | - |
15 | E770delinsEAYVM | - | - |
16 | G776delinsVC | - | - |
17 | V777delinsVGSP | - | - |
18 | E770delinsEAYVM | - | - |
19 | E770delinsEAYVM | - | - |
20 | V777delinsVGSP | - | - |
21 | E770delinsEAYVM | - | - |
36 | E770_A771insAYVM | - | - |
Treatment | No. (%) (n=36) | Best response |
---|---|---|
Targeted therapy | 5 (13.9) | |
Erlotinib | 1 | PR |
Gefitinib | 2 | SD (n=2) |
Afatinib | 1 | PR |
Crizotinib | 1 | PD |
Cytotoxic chemotherapy | 28 (77.8) | |
Pemetrexed+cisplatin | 23 | PR (n=6), SD (n=15), PD (n=1), N/A (n=1) |
Gemcitabine+cisplatin | 4 | PR (n=3), SD (n=1) |
Pemetrexed monotherapy | 1 | N/A |
Immunotherapy | 3 (8.3) | |
Durvalumab+tremelimumab+pemetrexed+cisplatin | 1 | SD |
Ipilimumab+nivolumab | 1 | SD |
Nivolumab | 1 | PR |
Values are presented as number (%). HER2, human epidermal growth factor receptor 2; ECOG PS, Eastern Cooperative Oncology Group performance status; LN, lymph node; LMS, leptomeningeal seeding; ADC, adenocarcinoma; SQC, squamous cell carcinoma; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.
HER2, human epidermal growth factor receptor 2.
HER2, human epidermal growth factor receptor 2; PR, partial response; SD, stable disease; PD, progressive disease; N/A, not acquired.